Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A supplementary phase 1b study to evaluate safety, tolerance and exposure of KAND567 administered intravenously in healthy subjects

Next Previous
Trial Profile

A supplementary phase 1b study to evaluate safety, tolerance and exposure of KAND567 administered intravenously in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KAND-567 (Primary)
  • Indications Autoimmune disorders; Breast cancer; Cancer; Cancer pain; Cardiovascular disorders; Myocardial infarction; Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Kancera

Most Recent Events

  • 19 Feb 2021 Status changed from recruiting to completed, according to a Kancera media release.
  • 06 Mar 2020 Results fom the final part of this study published in the Kancera Media Release
  • 05 Feb 2020 According to an Kancera media release, the company has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND567.The company estimates that the results of the study may become available in March 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top